Carregant...
Nintedanib in NSCLC: evidence to date and place in therapy
The treatment of advanced non-small cell lung cancer (NSCLC) is currently driven by the detection of targetable oncogenic drivers, i.e. epidermal growth factor receptor, echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase, etc. Those patients who are wildtype for known and va...
Guardat en:
| Publicat a: | Ther Adv Med Oncol |
|---|---|
| Autors principals: | , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4872248/ https://ncbi.nlm.nih.gov/pubmed/27239237 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834016630976 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|